 James Liu
Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Estrogens | 8 | 2020 | 329 | 2.850 |
Why?
| | Leiomyoma | 3 | 2021 | 45 | 1.560 |
Why?
| | Postmenopause | 6 | 2021 | 305 | 1.560 |
Why?
| | Norpregnadienes | 2 | 2021 | 7 | 1.480 |
Why?
| | Vaginal Creams, Foams, and Jellies | 2 | 2018 | 6 | 1.270 |
Why?
| | Dyspareunia | 2 | 2018 | 8 | 1.270 |
Why?
| | Vulva | 2 | 2018 | 24 | 1.260 |
Why?
| | Estrogen Replacement Therapy | 6 | 2020 | 117 | 1.220 |
Why?
| | Vagina | 4 | 2021 | 150 | 1.180 |
Why?
| | Estradiol | 4 | 2021 | 473 | 1.180 |
Why?
| | Ovary | 4 | 2020 | 205 | 0.930 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2023 | 53 | 0.870 |
Why?
| | Ovarian Neoplasms | 3 | 2020 | 420 | 0.860 |
Why?
| | Contraceptive Devices, Female | 1 | 2021 | 9 | 0.800 |
Why?
| | Pregnenediones | 1 | 2021 | 21 | 0.780 |
Why?
| | Uterine Neoplasms | 2 | 2018 | 76 | 0.760 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2020 | 10 | 0.750 |
Why?
| | Hormone Antagonists | 1 | 2020 | 40 | 0.740 |
Why?
| | Salpingo-oophorectomy | 1 | 2020 | 12 | 0.740 |
Why?
| | Menopause, Premature | 1 | 2020 | 8 | 0.740 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2018 | 143 | 0.710 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2020 | 193 | 0.660 |
Why?
| | Androgen Antagonists | 1 | 2019 | 70 | 0.660 |
Why?
| | Uterine Hemorrhage | 1 | 2018 | 36 | 0.660 |
Why?
| | Breast Neoplasms | 2 | 2020 | 1959 | 0.650 |
Why?
| | Vaginal Diseases | 1 | 2017 | 17 | 0.620 |
Why?
| | Osteoporosis | 1 | 2020 | 226 | 0.610 |
Why?
| | Hysterectomy | 2 | 2018 | 117 | 0.610 |
Why?
| | Pyrimidines | 1 | 2020 | 382 | 0.590 |
Why?
| | Cardiovascular System | 1 | 2018 | 127 | 0.570 |
Why?
| | Transgender Persons | 1 | 2019 | 135 | 0.570 |
Why?
| | Testosterone | 2 | 2019 | 350 | 0.560 |
Why?
| | Pituitary Neoplasms | 3 | 2015 | 165 | 0.480 |
Why?
| | Double-Blind Method | 6 | 2021 | 1683 | 0.480 |
Why?
| | Pneumocephalus | 1 | 2013 | 2 | 0.460 |
Why?
| | Reproductive Medicine | 1 | 2012 | 13 | 0.430 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2012 | 34 | 0.410 |
Why?
| | Female | 26 | 2023 | 61266 | 0.410 |
Why?
| | Hot Flashes | 1 | 2012 | 72 | 0.400 |
Why?
| | Endocrinology | 1 | 2012 | 68 | 0.400 |
Why?
| | Atrophy | 4 | 2021 | 164 | 0.380 |
Why?
| | Endoscopy | 1 | 2013 | 271 | 0.370 |
Why?
| | Adenoma | 2 | 2015 | 190 | 0.370 |
Why?
| | Sleep Deprivation | 1 | 2012 | 164 | 0.350 |
Why?
| | Humans | 30 | 2023 | 118273 | 0.330 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2007 | 6 | 0.300 |
Why?
| | Gonadotropins, Pituitary | 1 | 2007 | 22 | 0.300 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 528 | 0.280 |
Why?
| | Follicle Stimulating Hormone | 1 | 2007 | 216 | 0.270 |
Why?
| | Postoperative Complications | 2 | 2015 | 2230 | 0.270 |
Why?
| | Administration, Intravaginal | 4 | 2021 | 21 | 0.260 |
Why?
| | Drainage | 2 | 2015 | 158 | 0.230 |
Why?
| | Craniotomy | 1 | 2023 | 69 | 0.220 |
Why?
| | Menopause | 2 | 2015 | 266 | 0.210 |
Why?
| | Wakefulness | 1 | 2023 | 128 | 0.210 |
Why?
| | Skull Base | 1 | 2022 | 44 | 0.210 |
Why?
| | Skull Base Neoplasms | 1 | 2022 | 29 | 0.210 |
Why?
| | Intraoperative Complications | 1 | 2023 | 133 | 0.210 |
Why?
| | Progesterone | 2 | 2021 | 242 | 0.210 |
Why?
| | Middle Aged | 10 | 2018 | 27512 | 0.200 |
Why?
| | Ethinyl Estradiol | 1 | 2021 | 17 | 0.200 |
Why?
| | Endometrium | 2 | 2015 | 61 | 0.200 |
Why?
| | Treatment Outcome | 5 | 2023 | 9319 | 0.200 |
Why?
| | Phytoestrogens | 1 | 2020 | 17 | 0.190 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2020 | 26 | 0.190 |
Why?
| | Adult | 11 | 2023 | 31325 | 0.190 |
Why?
| | Contraceptive Agents | 1 | 2021 | 56 | 0.190 |
Why?
| | Genes, BRCA2 | 1 | 2020 | 25 | 0.180 |
Why?
| | Genes, BRCA1 | 1 | 2020 | 31 | 0.180 |
Why?
| | Drug Combinations | 1 | 2021 | 291 | 0.180 |
Why?
| | Seizures | 1 | 2023 | 345 | 0.180 |
Why?
| | Pregnancy | 5 | 2021 | 5672 | 0.180 |
Why?
| | Neuroprotection | 1 | 2019 | 31 | 0.180 |
Why?
| | Sex Reassignment Procedures | 1 | 2019 | 3 | 0.170 |
Why?
| | Amenorrhea | 1 | 2018 | 28 | 0.170 |
Why?
| | Pruritus Vulvae | 1 | 2018 | 1 | 0.160 |
Why?
| | Candidiasis, Vulvovaginal | 1 | 2018 | 5 | 0.160 |
Why?
| | Administration, Oral | 1 | 2020 | 753 | 0.160 |
Why?
| | Administration, Topical | 1 | 2018 | 141 | 0.150 |
Why?
| | Receptors, Progesterone | 2 | 2021 | 325 | 0.150 |
Why?
| | Symptom Assessment | 1 | 2018 | 123 | 0.150 |
Why?
| | Sinus Pericranii | 1 | 2016 | 1 | 0.150 |
Why?
| | Superior Sagittal Sinus | 1 | 2016 | 3 | 0.150 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.150 |
Why?
| | Cross-Over Studies | 1 | 2018 | 456 | 0.150 |
Why?
| | Decorin | 1 | 2015 | 6 | 0.140 |
Why?
| | Algorithms | 2 | 2015 | 1522 | 0.130 |
Why?
| | Meningioma | 1 | 2016 | 82 | 0.130 |
Why?
| | Meningeal Neoplasms | 1 | 2016 | 90 | 0.130 |
Why?
| | Peritoneum | 1 | 2015 | 36 | 0.130 |
Why?
| | Myometrium | 1 | 2015 | 35 | 0.130 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2015 | 28 | 0.130 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 28 | 0.130 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2015 | 19 | 0.130 |
Why?
| | Proteoglycans | 1 | 2015 | 109 | 0.130 |
Why?
| | Hormone Replacement Therapy | 1 | 2015 | 80 | 0.130 |
Why?
| | Product Labeling | 1 | 2014 | 5 | 0.130 |
Why?
| | Endometriosis | 1 | 2015 | 42 | 0.130 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1378 | 0.130 |
Why?
| | Follow-Up Studies | 1 | 2023 | 4574 | 0.120 |
Why?
| | Optic Chiasm | 1 | 2013 | 18 | 0.110 |
Why?
| | Cerebral Ventricles | 1 | 2013 | 48 | 0.110 |
Why?
| | Mobile Applications | 1 | 2015 | 145 | 0.110 |
Why?
| | Fertility Agents, Female | 1 | 2012 | 19 | 0.110 |
Why?
| | Triptorelin Pamoate | 1 | 2012 | 19 | 0.110 |
Why?
| | Cognition | 1 | 2019 | 1026 | 0.110 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2012 | 30 | 0.100 |
Why?
| | Pregnancy, Ectopic | 1 | 2012 | 53 | 0.100 |
Why?
| | Chorionic Gonadotropin | 1 | 2012 | 80 | 0.100 |
Why?
| | Vasomotor System | 1 | 2012 | 47 | 0.100 |
Why?
| | Surgical Flaps | 1 | 2013 | 118 | 0.100 |
Why?
| | Spermatocidal Agents | 1 | 2010 | 5 | 0.100 |
Why?
| | Nonoxynol | 1 | 2010 | 5 | 0.100 |
Why?
| | Weight Reduction Programs | 1 | 2012 | 93 | 0.100 |
Why?
| | Betaine | 1 | 2010 | 64 | 0.090 |
Why?
| | Aged | 4 | 2018 | 19597 | 0.090 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2010 | 86 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2659 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4684 | 0.090 |
Why?
| | Nose | 2 | 2022 | 58 | 0.080 |
Why?
| | Ovulation | 1 | 2008 | 41 | 0.080 |
Why?
| | Luteal Phase | 1 | 2008 | 44 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2023 | 12931 | 0.080 |
Why?
| | Cohort Studies | 1 | 2018 | 5077 | 0.080 |
Why?
| | Quality of Life | 1 | 2018 | 2355 | 0.080 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 610 | 0.080 |
Why?
| | Gynatresia | 1 | 2006 | 1 | 0.070 |
Why?
| | Fertility | 1 | 2007 | 135 | 0.070 |
Why?
| | Infertility, Female | 1 | 2006 | 94 | 0.070 |
Why?
| | Surrogate Mothers | 1 | 2004 | 2 | 0.060 |
Why?
| | Mental Disorders | 1 | 2013 | 935 | 0.060 |
Why?
| | Embryo Transfer | 1 | 2004 | 28 | 0.060 |
Why?
| | Ovulation Induction | 1 | 2004 | 50 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 2006 | 328 | 0.060 |
Why?
| | Infertility | 1 | 2004 | 45 | 0.060 |
Why?
| | Piperazines | 1 | 2006 | 316 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 2433 | 0.060 |
Why?
| | Ultrasonography | 1 | 2007 | 714 | 0.050 |
Why?
| | Otolaryngologists | 1 | 2022 | 13 | 0.050 |
Why?
| | Risk Factors | 2 | 2015 | 8957 | 0.050 |
Why?
| | Biomarkers | 1 | 2012 | 3568 | 0.050 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 215 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 3169 | 0.050 |
Why?
| | Male | 3 | 2023 | 57478 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2012 | 1968 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2022 | 164 | 0.050 |
Why?
| | Artificial Intelligence | 1 | 2021 | 137 | 0.050 |
Why?
| | Obesity | 1 | 2012 | 2715 | 0.040 |
Why?
| | Aging | 1 | 2008 | 1675 | 0.040 |
Why?
| | Angiography, Digital Subtraction | 1 | 2016 | 46 | 0.040 |
Why?
| | Promegestone | 1 | 2015 | 33 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 135 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 174 | 0.030 |
Why?
| | Income | 1 | 2015 | 173 | 0.030 |
Why?
| | Endometrial Neoplasms | 1 | 2015 | 144 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 345 | 0.030 |
Why?
| | Educational Status | 1 | 2015 | 437 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 1186 | 0.030 |
Why?
| | Biopsy | 1 | 2015 | 1078 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 701 | 0.020 |
Why?
| | Laparoscopy | 1 | 2015 | 417 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1681 | 0.020 |
Why?
| | Gels | 1 | 2010 | 72 | 0.020 |
Why?
| | Pregnanediol | 1 | 2008 | 12 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 2837 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 2990 | 0.020 |
Why?
| | Estrone | 1 | 2008 | 36 | 0.020 |
Why?
| | Decision Making | 1 | 2015 | 806 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3155 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2262 | 0.020 |
Why?
| | Young Adult | 2 | 2015 | 10729 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2006 | 57 | 0.020 |
Why?
| | Sulfones | 1 | 2006 | 98 | 0.020 |
Why?
| | Purines | 1 | 2006 | 160 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2015 | 6541 | 0.020 |
Why?
| | Women's Health | 1 | 2006 | 274 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 6443 | 0.010 |
Why?
| | United States | 1 | 2015 | 12495 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2008 | 4522 | 0.010 |
Why?
| | Adolescent | 1 | 2010 | 18364 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|